Global Prader-Willi Syndrome Drug Market, By Type (Paternal Deletion, Maternal Uniparental Disomy (UPD), Imprinting Defect), Branded Drugs (Genotropin, Omnitrope Norditropin, Others), Diagnosis (Physical Examination, Genetic Testing, Blood Test), Therapy (Hormonal Therapy, Physical therapy, Behavioral Therapy), Treatment (Medications, Dietary treatment, Human Growth Hormone replacement, Sex hormone Replacement), Route of Administration (Oral, Subcutaneous, Intranasal, Others), Distribution Channel (Direct, Online Pharmacy, Retailers, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.